secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0000950170-24-108629
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences reports positive interim Phase 1a results for ABI-5366 in recurrent genital herpes
--------------------------------------------------------------------------------

- ABI-5366 was well-tolerated with favorable safety profile and exposure up to 70 days in healthy participants.
- Half-life of approximately 20 days supports both once-weekly and once-monthly oral dosing schedules.
- Screening for Phase 1b in participants with recurrent genital herpes is now underway.
- Interim Phase 1b results are expected in the first half of 2025.
- Single doses of ABI-5366 surpassed target plasma concentrations for antiviral efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/0000950170-24-108629-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024108629/asmb-20240923.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-108629

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer